Loading
Genelux Corp Stock: price and insider trades · United States
US·Mcap US$109.5M
No insider purchase over the last 90 days. The latest was filed 07 Jun 2024.
Genelux Corp: what insiders have been doing
Genelux Corp is a listed company. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 11 insiders published 24 filings.
Only sales appear on the open market, 14 sales in all totalling €144k, filed by 5 insiders. One trade stands out by size: a sale of €43k from Thomas John, disclosed on 2 December 2025.
Compared with its exchange (5,458 companies, median 22 filings), a count of 24 filings is above the norm. Since 2023, the database holds 10 purchases and 64 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 8,000 USD and net income at -32.1 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
141
Thresholds
n/a
Buy Volume
€1,144
10 ops. · all time
Sell Volume
€8M
64 ops. · all time
Who traded when
BuySaleJoseph Cappello5 sales
Ralph Smalling5 sales
Thomas Zindrick5 sales
Yong Yu4 sales
John Thomas2 sales
James L. Tyree1 sale
+2 other insiders
Since the insiders bought
- +13.4%Entry US$2.39 · Close at T+365 US$2.71
- +13.4%Entry US$2.39 · Close at T+365 US$2.71
- +13.4%Entry US$2.39 · Close at T+365 US$2.71
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.42
Analyst consensus
6 analysts1.17/5
US$12.00Target US$18.83(+678%)US$31.00
Income statement
RevenueUS$8k
EBITDA-US$32.6M-408000% margin
Net income-US$32.1M-401812.5% margin
Valuation
PER (forward)-3.2x
P/Book6.7x
Beta0.58
Balance sheet & cash
Market capUS$109.5M
Total debtUS$1.7M
Free Cash Flow-US$26.4M
Debt / Equity15%
Profitability & ownership
ROE-177.9%
ROA-77.9%
% insiders12.9%
% institutions31.2%
Last declaration on 4 August 2026
Declarations141 total
653 shares@ US$2.94670.0017% mcap1.6% of flowCommon StockSEC:0001493152-26-036076:0
3,023 shares@ US$2.94590.0077% mcap2.6% of flowCommon StockSEC:0001493152-26-036075:0
12,000 shares@ US$2.90820.031% mcap100.0% of flowCommonSEC144:0001950047-26-006798
28,409 sharesCommon StockSEC:0001493152-26-029418:0
174,841 sharesCommon StockSEC:0001493152-26-029419:0
28,409 sharesCommon StockSEC:0001493152-26-029413:0
28,409 sharesCommon StockSEC:0001493152-26-029415:0
28,409 sharesCommon StockSEC:0001493152-26-029416:0
730,601 sharesCommon StockSEC:0001493152-26-029417:0
233,957 sharesCommon StockSEC:0001493152-26-029420:0
278,906 sharesCommon StockSEC:0001493152-26-029421:0
192 shares@ US$2.930.0005% mcap1.4% of flowCommon StockSEC:0001493152-26-027348:0
345 shares@ US$2.422.1% of flowCommon StockSEC:0001493152-26-012972:0
906 shares@ US$2.421.8% of flowCommon StockSEC:0001493152-26-012971:0
3,582 shares@ US$2.422.5% of flowCommon StockSEC:0001493152-26-012969:0
10,000 shares@ US$2.89579.9% of flowCommon StockSEC:0001493152-26-008743:0
12,673 shares@ US$3.326712.4% of flowCommon StockSEC:0001493152-25-027339:0
1,270 shares@ US$3.32673.5% of flowCommon StockSEC:0001493152-25-027337:0
1,244 shares@ US$3.357410.5% of flowCommon StockSEC:0001493152-25-026981:0
10,000 shares@ US$5.000817.4% of flowCommon StockSEC:0001493152-25-025811:0
10,000 shares0Common StockSEC:0001641172-25-026396:0
25 of 141 declarations
About Genelux Corp
Genelux Corp is a NASDAQ-listed company focused on developing innovative therapies for cancer treatment. It specializes in the use of oncolytic virus technology to target and destroy cancer cells.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
